Inozyme reports positive trial data for rare disease treatments

BOSTON - Inozyme Pharma Inc. (NASDAQ:INZY), a biopharmaceutical company specializing in treatments for rare diseases, has announced favorable trial results for its drug candidate INZ-701. The ongoing Phase 1/2 clinical trials indicated promising safety and efficacy in treating ABCC6 Deficiency, commonly known as pseudoxanthoma elasticum (PXE), and ENPP1 Deficiency.

In patients with ABCC6 Deficiency, the study showed potential improvements in vascular pathology and visual function. Notably, seven of eight evaluable patients experienced a reduction or stabilization in carotid intima-media thickness (cIMT), a marker for cardiovascular disease and stroke risk. Additionally, increased choroidal thickness was observed, suggesting a potential benefit for retinal disease. Improvements in visual function, as measured by the Global Visual Function Questionnaire (VFQ-25), were also reported.

For ENPP1 Deficiency, the trial revealed significant reductions in fibroblast growth factor-23 (FGF-23) and changes in bone metabolism markers, indicating potential restoration of bone mineralization. Patient-Reported Outcome Measurement Information Scales (PROMIS) showed maintained favorable responses in pain and fatigue.

Both conditions showed a favorable safety profile for INZ-701 with no serious or severe adverse events reported. The drug also exhibited a favorable immunogenicity profile with low titers of non-neutralizing anti-drug antibodies (ADAs).

The natural history study conducted by Inozyme highlighted the high risk of stroke in pediatric patients with ABCC6 Deficiency, emphasizing the need for early intervention. In light of these findings, Inozyme plans to initiate a pivotal trial in pediatric patients with ABCC6 Deficiency in Q1 2025, subject to regulatory review and sufficient funding.

The company's development plans are bolstered by these results, which suggest that INZ-701 may address the unmet medical needs of patients with these rare diseases. Inozyme is working with regulatory authorities to design a pivotal trial that could potentially lead to accelerated approval in the United States and conditional marketing authorization in the European Union.

This announcement is based on a press release statement from Inozyme Pharma Inc.

Inozyme Pharma Inc. (NASDAQ:INZY) has been making headlines with its latest clinical trial results, but what does the financial landscape look like for this biopharmaceutical innovator? According to InvestingPro, Inozyme holds more cash than debt on its balance sheet, which is a positive sign for potential investors looking for a company with a stable financial footing. This could be particularly important as the company prepares for the pivotal trial in pediatric patients with ABCC6 Deficiency.

Get The News You Want

Read market moving news with a personalized feed of stocks you care about.

Get The App

On the flip side, one of the InvestingPro Tips suggests that Inozyme is quickly burning through cash. With a reported operating income of -75.64M USD for the last twelve months as of Q4 2023, it's clear that the company is investing heavily in its development pipeline. This aligns with the company's strategic focus on bringing INZ-701 to market, despite not being profitable over the same period, as indicated by a negative P/E ratio of -5.56.

However, the company's stock has experienced a large price uptick over the last six months, with a 66.06% total return, reflecting investor optimism following the positive trial results. This could suggest growing confidence in the company's long-term potential. It's worth noting that Inozyme does not pay a dividend, which is typical for companies in the growth phase focusing on reinvestment.

Investors looking for a deeper dive into Inozyme Pharma can find additional InvestingPro Tips at InvestingPro. There are 6 more tips available that could help in making a more informed investment decision. And for those ready to take the next step, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.